Evidence map›Paper›PMID 35684388›Full record

ArticleMolecules (Basel, Switzerland)2022

Borylated 2,3,4,5-Tetrachlorophthalimide and Their 2,3,4,5-Tetrachlorobenzamide Analogues: Synthesis, Their Glycosidase Inhibition and Anticancer Properties in View to Boron Neutron Capture Therapy.

David M Campkin, Yuna Shimadate, Barbara Bartholomew, Paul V Bernhardt, Robert J Nash, Jennette A Sakoff, Atsushi Kato, Michela I Simone

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Construction of targetedFrontiers in oncology · 2023
    Article
  7. Women in Bioorganic Chemistry.Molecules (Basel, Switzerland) · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 3 countries.

David M CampkinDiscipline of Chemistry, University of Newcastle, Callaghan, NSW 2308, Australia.
Yuna ShimadateDepartment of Hospital Pharmacy, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.
Barbara BartholomewPhytoquest Ltd., Plas Gogerddan, Aberystwyth, Ceredigion SY23 3EB, UK.
Paul V BernhardtSchool of Chemistry & Molecular Biosciences, University of Queensland, Brisbane, QLD 4072, Australia.
Robert J NashPhytoquest Ltd., Plas Gogerddan, Aberystwyth, Ceredigion SY23 3EB, UK.ORCID 0000-0002-3272-640X
Jennette A SakoffPriority Research Centre for Drug Development, University of Newcastle, Callaghan, NSW 2308, Australia.
Atsushi KatoDepartment of Hospital Pharmacy, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.ORCID 0000-0001-8022-196X
Michela I SimoneDiscipline of Chemistry, University of Newcastle, Callaghan, NSW 2308, Australia.
Aberystwyth University · GBToyama University Hospital · JPUniversity of Newcastle Australia · AUCalvary Mater Newcastle Hospital · AUThe University of Queensland · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tetrachlorinated phthalimide analogues bearing a boron-pinacolate ester group were synthesised via two synthetic routes and evaluated in their glycosidase modulating and anticancer properties, with a view to use them in boron neutron capture therapy (BNCT), a promising radiation type for cancer, as this therapy does little damage to biological tissue. An unexpected decarbonylation/decarboxylation to five 2,3,4,5-tetrachlorobenzamides was observed and confirmed by X-ray crystallography studies, thus, giving access to a family of borylated 2,3,4,5-tetrachlorobenzamides. Biological evaluation showed the benzamide drugs to possess good to weak potencies (74.7-870 μM) in the inhibition of glycosidases, and to have good to moderate selectivity in the inhibition of a panel of 18 glycosidases. Furthermore, in the inhibition of selected glycosidases, there is a core subset of three animal glycosidases, which is always inhibited (rat intestinal maltase α-glucosidase, bovine liver β-glucosidase and β-galactosidase). This could indicate the involvement of the boron atom in the binding. These glycosidases are targeted for the management of diabetes, viral infections (via a broad-spectrum approach) and lysosomal storage disorders. Assays against cancer cell lines revealed potency in growth inhibition for three molecules, and selectivity for one of these molecules, with the growth of the normal cell line MCF10A not being affected by this compound. One of these molecules showed both potency and selectivity; thus, it is a candidate for further study in this area. This paper provides numerous novel aspects, including expedited access to borylated 2,3,4,5-tetrachlorophthalimides and to 2,3,4,5-tetrachlorobenzamides. The latter constitutes a novel family of glycosidase modulating drugs. Furthermore, a greener synthetic access to such structures is described.

Indexed as

Boron Neutron Capture TherapyNeoplasmsAnimalsBoronBoron CompoundsCattleGlycoside HydrolasesRatsBoronBoron CompoundsGlycoside Hydrolasesbenzamideboronboron neutron capture therapycancerglycosidasephthalimide

Identifiers

PMID35684388
PMCPMC9182199
OpenAlexW4281612669

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.